November 1982

Platelet—Arterial Synthetic Graft Interaction and Its Modification

Author Affiliations

From the Departments of Surgery (Drs Callow, Connolly, O'Donnell, Gembarowicz, and Keough) and Nuclear Medicine (Ms Ramberg-Laskaris), Tufts-New England Medical Center, and the US Naval Blood Research Laboratory (Dr Valeri), Boston.

Arch Surg. 1982;117(11):1447-1455. doi:10.1001/archsurg.1982.01380350047007

• We compared the in vivo platelet reactivity of two commonly used clinical grafts, Dacron and expanded polytetrafluoroethylene (PTFE), with that of a control autogenous artery graft and assessed whether platelet reactivity was modified by the platelet-antiaggregating agent prostacyclin (PGI2) (epoprostenol). Grafts were randomly placed into the carotid arteries of 21 baboons. Platelets labeled with indium 111 were infused within one hour after implantation graft for gamma camera scanning of platelet uptake. The accumulation of platelets on Dacron grafts began almost immediately after injection and reached a peak after one to two hours. The PTFE and control autogenous artery grafts accumulated comparable small amounts of platelets. Prostacyclin was then infused in a second series of baboons with Dacron grafts, at a rate of 150 to 200 ng/kg/min. It prevented the usual platelet uptake when administered concomitant with graft implantation and reduced previously established platelet activity.

(Arch Surg 1982;117:1447-1455)